Physiologically-based pharmacokinetic model for Fentanyl in support of the development of Provisional Advisory Levels.
暂无分享,去创建一个
[1] L. Mather. Clinical Pharmacokinetics of Fentanyl and its Newer Derivatives , 1983, Clinical pharmacokinetics.
[2] T. Gillespie,et al. Age and Fentanyl Pharmacokinetics , 1982, Anesthesia and analgesia.
[3] H. Striebel,et al. [Pharmacokinetics of intranasal Fentanyl.]. , 1993, Schmerz.
[4] D. Fung,et al. Fentanyl Pharmacokinetics in Awake Volunteers , 1980, Journal of clinical pharmacology.
[5] R. Upton,et al. Pharmacokinetics, efficacy, and tolerability of fentanyl following intranasal versus intravenous administration in adults undergoing third-molar extraction: a randomized, double-blind, double-dummy, two-way, crossover study. , 2008, Clinical therapeutics.
[6] Q. Schiermeier. Hostage deaths put gas weapons in spotlight , 2002, Nature.
[7] D. Fisher,et al. PHARMACOKINETICS OF FENTANYL IN THE ELDERLY , 1988 .
[8] E. Kharasch,et al. Simultaneous Assessment of Drug Interactions with Low- and High-Extraction Opioids: Application to Parecoxib Effects on the Pharmacokinetics and Pharmacodynamics of Fentanyl and Alfentanil , 2003, Anesthesiology.
[9] Harvey J Clewell,et al. Use of a Physiologically Based Pharmacokinetic Model to Identify Exposures Consistent With Human Biomonitoring Data for Chloroform , 2006, Journal of toxicology and environmental health. Part A.
[10] A. Sandler,et al. A review of the use of fentanyl analgesia in the management of acute pain in adults. , 1999, Anesthesiology.
[11] V. Sunderland,et al. Pharmacokinetics of Nasal Fentanyl , 2003 .
[12] E. Kharasch,et al. Fentanyl metabolism by human hepatic and intestinal cytochrome P450 3A4: implications for interindividual variability in disposition, efficacy, and drug interactions. , 1997, Drug metabolism and disposition: the biological fate of chemicals.
[13] H. Magnussen,et al. PLASMA FENTANYL CONCENTRATIONS AND THE OCCURRENCE OF RESPIRATORY DEPRESSION IN VOLUNTEERS , 1982 .
[14] S. Baba,et al. Identification and quantitative determination of fentanyl metabolites in patients by gas chromatography--mass spectrometry. , 1984, Anesthesiology.
[15] Robert A Young,et al. Overview of the Standing Operating Procedure (SOP) for the development of Provisional Advisory Levels (PALs) , 2009, Inhalation toxicology.
[16] J. Svensson,et al. Morphine metabolism in cancer patients on increasing oral doses--no evidence for autoinduction or dose-dependence. , 1983, British journal of clinical pharmacology.
[17] D. R. Cook,et al. Double-blind comparison of oral transmucosal fentanyl citrate with oral meperidine, diazepam, and atropine as preanesthetic medication in children with congenital heart disease. , 1991, Anesthesiology.
[18] E. Hellriegel,et al. Comparison of Equivalent Doses of Fentanyl Buccal Tablets and Arteriovenous Differences in Fentanyl Pharmacokinetics , 2006, Clinical pharmacokinetics.
[19] H. W. Striebel,et al. Pharmakokinetische Studie zur intranasalen Gabe von Fentanyl , 1993, Der Schmerz.
[20] K. Hildebrand,et al. A review of intrathecal fentanyl and sufentanil for the treatment of chronic pain. , 2006, Pain medicine.
[21] Sven Björkman,et al. Comparative physiological pharmacokinetics of fentanyl and alfentanil in rats and humans based on parametric single-tissue models , 1994, Journal of Pharmacokinetics and Biopharmaceutics.
[22] T. Egan,et al. Dose Proportionality and Pharmacokinetics of Oral Transmucosal Fentanyl Citrate , 1998, Anesthesiology.
[23] Hudson Rj. Variability of fentanyl pharmacokinetics in neonates. , 1986 .
[24] K. A. East,et al. Oral Transmucosal Fentanyl Citrate (Lollipop) Premedication in Human Volunteers , 1989, Anesthesia and analgesia.
[25] Paul S Price,et al. Modeling Interindividual Variation in Physiological Factors Used in PBPK Models of Humans , 2003, Critical reviews in toxicology.
[26] Russell D. Wada,et al. Application of Physiologic Models to Predict the Influence of Changes in Body Composition and Blood Flows on the Pharmacokinetics of Fentanyl and Alfentanil in Patients , 1998, Anesthesiology.
[27] M. Danhof,et al. Mechanism-Based Pharmacokinetic-Pharmacodynamic Modeling of the Respiratory-Depressant Effect of Buprenorphine and Fentanyl in Rats , 2006, Journal of Pharmacology and Experimental Therapeutics.
[28] Gary M. Pollack,et al. Opioid Tolerance Development: A Pharmacokinetic/Pharmacodynamic Perspective , 2008, The AAPS Journal.
[29] Erratum to: A physiologically-based recirculatory meta-model for nasal fentanyl in man , 2012, Journal of Pharmacokinetics and Pharmacodynamics.
[30] M. Jamei,et al. PBPK modelling of inter-individual variability in the pharmacokinetics of environmental chemicals. , 2010, Toxicology.
[31] S J Farr,et al. Pulmonary administration of aerosolised fentanyl: pharmacokinetic analysis of systemic delivery. , 1998, British journal of clinical pharmacology.
[32] T. Hedner,et al. Pharmacokinetics and tolerability of different doses of fentanyl following sublingual administration of a rapidly dissolving tablet to cancer patients: a new approach to treatment of incident pain. , 2005, British journal of clinical pharmacology.
[33] Amin Rostami-Hodjegan,et al. Anatomical, Physiological and Metabolic Changes with Gestational Age during Normal Pregnancy , 2012, Clinical Pharmacokinetics.
[34] C. Coté,et al. Uptake pharmacokinetics of the Fentanyl Oralet® in children scheduled for central venous access removal: implications for the timing of initiating painful procedures , 2002, Paediatric anaesthesia.
[35] E. Tanaka,et al. Clinically important pharmacokinetic drug–drug interactions: role of cytochrome P450 enzymes , 1998, Journal of clinical pharmacy and therapeutics.
[36] Hugh A. Barton,et al. Database for Physiologically Based Pharmacokinetic (PBPK) Modeling: Physiological Data for Healthy and Health-Impaired Elderly , 2009, Journal of toxicology and environmental health. Part B, Critical reviews.
[37] H Harashima,et al. Comparative tissue concentration profiles of fentanyl and alfentanil in humans predicted from tissue/blood partition data obtained in rats. , 1990, Anesthesiology.
[38] E. Kharasch,et al. Influence of Hepatic and Intestinal Cytochrome P4503A Activity on the Acute Disposition and Effects of Oral Transmucosal Fentanyl Citrate , 2004, Anesthesiology.
[39] James C. Scott,et al. Electroencephalographic quantitation of opioid effect: comparative pharmacodynamics of fentanyl and sufentanil. , 1991, Anesthesiology.
[40] C. Coté,et al. The Pharmacokinetics of the Intravenous Formulation of Fentanyl Citrate Administered Orally in Children Undergoing General Anesthesia , 2004, Anesthesia and analgesia.
[41] D. Gardner,et al. Provisional Advisory Levels (PALs) for acrylonitrile , 2009, Inhalation toxicology.
[42] B. J. Peterson,et al. Oral transmucosal fentanyl citrate for analgesia and sedation in the emergency department. , 1991, Annals of emergency medicine.
[43] D. McClain,et al. Intravenous fentanyl kinetics , 1980, Clinical pharmacology and therapeutics.
[44] Nat Rothman,et al. Physiologically‐Based Pharmacokinetic Modeling of Benzene in Humans: A Bayesian Approach , 2006, Risk analysis : an official publication of the Society for Risk Analysis.
[45] H. Scheinin,et al. The Concentration-Effect Relationship of the Respiratory Depressant Effects of Alfentanil and Fentanyl , 2001, Anesthesia and analgesia.
[46] François Bouzom,et al. Physiologically based pharmacokinetic (PBPK) modelling tools: how to fit with our needs? , 2012, Biopharmaceutics & drug disposition.
[47] S. Harapat,et al. Tissue distribution of fentanyl and alfentanil in the rat cannot be described by a blood flow limited model , 1993, Journal of Pharmacokinetics and Biopharmaceutics.
[48] S. Schug,et al. Formulations of Fentanyl for the Management of Pain , 2012, Drugs.
[49] N. Pace,et al. Oral Transmucosal Fentanyl Citrate Premedication in Children , 1989, Anesthesia and analgesia.
[50] J. Silverstein,et al. An Analysis of the Duration of Fentanyl and Its Metabolites in Urine and Saliva , 1993, Anesthesia and analgesia.
[51] T. Sacco,et al. Balanced anestesia versus total intravenous anestesia for kidney transplantation. , 2006, Minerva anestesiologica.
[52] H J Clewell,et al. Development of a physiologically based pharmacokinetic model of trichloroethylene and its metabolites for use in risk assessment. , 2000, Environmental health perspectives.
[53] P M Schlosser,et al. Haber's rule: a special case in a family of curves relating concentration and duration of exposure to a fixed level of response for a given endpoint. , 2000, Toxicology.
[54] B. Crotty,et al. Epidural Fentanyl Effect on Cardiac Output and Hepatic Blood Flow , 1991 .
[55] Steven Edward Kern,et al. A pharmacokinetic study to compare two simultaneous 400 μg doses with a single 800 μg dose of oral transmucosal fentanyl citrate , 2003 .
[56] C. Prys‐roberts,et al. Ventilatory Depression Related to Plasma Fentanyl Concentrations during and after Anesthesia in Humans , 1983, Anesthesia and analgesia.
[57] M. Darwish,et al. Pharmacokinetics and Dose Proportionality of Fentanyl Effervescent Buccal Tablets in Healthy Volunteers , 2005, Clinical pharmacokinetics.
[58] M. Ashburn,et al. Absorption and bioavailability of oral transmucosal fentanyl citrate. , 1991, Anesthesiology.
[59] A. Zwart,et al. Concentration—time mortality response relationship of irritant and systemically acting vapours and gases , 1986 .
[60] Harvey J Clewell,et al. Reverse dosimetry: interpreting trihalomethanes biomonitoring data using physiologically based pharmacokinetic modeling , 2007, Journal of Exposure Science and Environmental Epidemiology.
[61] S. Björkman. Reduction and Lumping of Physiologically Based Pharmacokinetic Models: Prediction of the Disposition of Fentanyl and Pethidine in Humans by Successively Simplified Models , 2003, Journal of Pharmacokinetics and Pharmacodynamics.
[62] D R Stanski,et al. Decreased fentanyl and alfentanil dose requirements with age. A simultaneous pharmacokinetic and pharmacodynamic evaluation. , 1987, The Journal of pharmacology and experimental therapeutics.
[64] E. Kharasch,et al. Influence of Age on the Pharmacokinetics and Pharmacodynamics of Oral Transmucosal Fentanyl Citrate , 2004, Anesthesiology.
[65] C. Timperley,et al. Analysis of clothing and urine from Moscow theatre siege casualties reveals carfentanil and remifentanil use. , 2012, Journal of analytical toxicology.
[66] M. Mcclanahan,et al. Provisional Advisory Levels (PALs) for phosgene (CG) , 2009, Inhalation toxicology.
[67] R. Moore,et al. PLASMA FENTANYL CONCENTRATIONS AND CLINICAL OBSERVATIONS DURING AND AFTER OPERATION , 1979 .
[68] A. J. MacDonald,et al. The utility of PBPK in the safety assessment of chloroform and carbon tetrachloride. , 2000, Regulatory toxicology and pharmacology : RTP.
[69] E. Hellriegel,et al. Single‐Dose and Steady‐State Pharmacokinetics of Fentanyl Buccal Tablet in Healthy Volunteers , 2007, Journal of clinical pharmacology.
[70] J Bromilow,et al. Liver enzyme induction and inhibition: implications for anaesthesia , 2006, Anaesthesia.
[71] D. Gardner,et al. Provisional Advisory Levels (PALs) for hydrogen sulfide (H2S) , 2009, Inhalation toxicology.
[72] M. Delp,et al. Physiological Parameter Values for Physiologically Based Pharmacokinetic Models , 1997, Toxicology and industrial health.
[73] S. Kaasa,et al. Long term methadone for chronic pain: A pilot study of pharmacokinetic aspects , 2007, European journal of pain.